论文部分内容阅读
目的研究并探讨重组人血管内皮抑制素注射液(恩度)与化疗联合治疗多种晚期恶性肿瘤的临床疗效。方法 160例晚期恶性肿瘤患者,随机分为观察组和对照组,每组80例。对照组给予化疗治疗,观察组采用恩度联合化疗进行治疗,比较两组患者的临床疗效。结果治疗后,观察组有效率明显优于对照组,差异有统计学意义(P<0.05)。结论恩度与化疗联合治疗多种晚期恶性肿瘤的临床疗效显著,可提高患者的生活质量,降低不良反应发生率低,具有安全性,值得临床推广及应用。
Objective To study and explore the clinical efficacy of recombinant human endostatin injection (Endo) in combination with chemotherapy in the treatment of various advanced malignancies. Methods One hundred and sixty patients with advanced malignant tumor were randomly divided into observation group and control group with 80 cases in each group. The control group was given chemotherapy, the observation group was treated with Endo combined with chemotherapy, and the clinical efficacy was compared between the two groups. Results After treatment, the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusions The combination of Endue and chemotherapy for the treatment of various advanced malignancies has significant clinical effect, which can improve the quality of life of patients, reduce the incidence of adverse reactions, have safety, and worthy of clinical promotion and application.